Log in to search using one of your social media accounts:

 

Menlo Therapeutics Raises $50M
venBio leads Series C Financing of oral once-daily Anti-Pruritus Therapy in development for Pruritus of Atopic Dermatitis, Psoriasis and Prurigo Nodularis, and for Refractory Chronic Cough MENLO PARK, Calif., July 18, 2017 -- (Healthcare Sales & Marketi... Biopharmaceuticals, Venture Capital Menlo Therapeutics, Serlopitant, pruritus (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - July 18, 2017 Category: Pharmaceuticals Source Type: news

Novartis unit Alcon posts modest Q2 gain
(Reuters) — Long-suffering Novartis (NYSE:NVS) unit Alcon‘s sales growth accelerated in the second quarter, boosting options for the business including a possible disposal, CEO Joe Jimenez said today. The eye care subsidiary’s sales rose 1% to $1.5 billion, including intraocular lens revenues, which grew for the first time in the second quarter since 2014. Spending continued to promote products with eye surgeons, resulting in a $19 million operating loss. Novartis has been reviewing Alcon for a possible disposal, with an update slated for this year. All options are under consideration, Jimenez reiter...
Source: Mass Device - July 18, 2017 Category: Medical Devices Authors: Brad Perriello Tags: MassDevice Earnings Roundup Mergers & Acquisitions Optical/Ophthalmic Wall Street Beat Alcon Novartis Source Type: news

Philips partners with West Physics for CT radiation dose control program
Royal Philips (NYSE:PHG) said today it is partnering with West Physics to create a turn-key computed tomography radiation dose management program. The companies said that their new partnered radiation dose management program will help health systems comply with new dose management requirements from accrediting regulatory bodies, helping hospitals establish effective radiation safety programs to optimize radiation dose delivery. “In today’s shifting regulatory environment, hospitals really must look ahead to remain compliant with evolving requirements for CT dose optimization. With guidance from our team of...
Source: Mass Device - July 17, 2017 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Imaging royalphilips Source Type: news

Janssen Biotech ’s Tremfya receives FDA approval for plaque psoriasis treatment
The US Food and Drug Administration (FDA) has granted approval for Janssen Biotech ’s Tremfya (guselkumab) to treat adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - July 16, 2017 Category: Pharmaceuticals Source Type: news

FDA OKs Biologic Guselkumab (Tremfya) for Plaque Psoriasis FDA OKs Biologic Guselkumab (Tremfya) for Plaque Psoriasis
Guselkumab is the first and only approved biologic agent that selectively blocks interleukin-23, a key player in plaque psoriasis.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 14, 2017 Category: Consumer Health News Tags: Dermatology News Alert Source Type: news

FDA OKs Guselkumab for Plaque Psoriasis
(MedPage Today) -- First selective IL-23 blocker to reach market (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - July 14, 2017 Category: American Health Source Type: news

Morphosys sees revenue boost from Janssen psoriasis drug
DUESSELDORF/FRANKFURT (Reuters) - German biotech group Morphosys expects to receive royalties from psoriasis drug guselkumab for five months this year, its Chief Executive Simon Moroney said, after its licensee received U.S. regulatory approval. (Source: Reuters: Health)
Source: Reuters: Health - July 14, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Morphosys sees revenue boost as FDA approves psoriasis drug
DUESSELDORF/FRANKFURT (Reuters) - German biotech group Morphosys expects to receive royalties for its psoriasis drug guselkumab for five months this year, its Chief Executive Simon Moroney said, after its licensee received U.S. regulatory approval. (Source: Reuters: Health)
Source: Reuters: Health - July 14, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Novartis confirms 5 year data for first and only fully-human IL-17A inhibitor Cosentyx ® reinforcing sustained efficacy and safety profile in psoriasis
Novartis, a global leader in Immunology & Dermatology, confirmed today positive 5 year efficacy and safety results for Cosentyx® from a Phase III long-term extension study in patients with moderate-to-severe plaque psoriasis[1]. Data will be presented at a key medical congress in the second half of 2017. (Source: World Pharma News)
Source: World Pharma News - July 14, 2017 Category: Pharmaceuticals Tags: Featured Novartis Business and Industry Source Type: news

Morphosys jumps as FDA approves psoriasis drug
FRANKFURT (Reuters) - Shares in Morphosys jumped 9 percent on Friday after a licensee won U.S. approval for psoriasis drug guselkumab, bringing the German biotech group a step closer to launching its first antibody drug on to the market. (Source: Reuters: Health)
Source: Reuters: Health - July 14, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Morphosys jumps pre-market as FDA approves antibody drug
FRANKFURT (Reuters) - Shares in Morphosys jumped 11 percent in pre-market trade on Friday after a licensee won U.S. approval for psoriasis drug guselkumab, bringing the German biotech group a step closer to launching its first antibody drug onto the market. (Source: Reuters: Health)
Source: Reuters: Health - July 14, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Janssen announces u.s. fda approval of tremfya ™ (guselkumab) for the treatment of moderate to severe plaque psoriasis
(Source: Johnson and Johnson)
Source: Johnson and Johnson - July 14, 2017 Category: Pharmaceuticals Source Type: news

FDA OKs new Johnson & Johnson treatment for psoriasis
People with psoriasis will have a new treatment option, after U.S. regulators approved a drug from Johnson & Johnson (Source: ABC News: Health)
Source: ABC News: Health - July 13, 2017 Category: Consumer Health News Tags: Health Source Type: news

Janssen Announces FDA Approval of Tremfya (guselkumab) for the Treatment of Moderate to Severe Plaque Psoriasis
Horsham, PA, July 13, 2017 ― Janssen Biotech, Inc. (Janssen) announced today that the U.S. Food and Drug Administration (FDA) has approved Tremfya (guselkumab) for the treatment of adults living with moderate to severe plaque psoriasis who are... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - July 13, 2017 Category: Drugs & Pharmacology Source Type: news

MassDevice.com +5 | The top 5 medtech stories for July 13, 2017
Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry. Get this in your inbox everyday by subscribing to our newsletters.   5. Philips wins FDA nod for BlueControl psoriasis treatment device Royal Philips said today it won FDA 510(k) clearance for its BlueControl wearable light therapy designed to treat mild psoriasis. The Amsterdam-based company&rsquo...
Source: Mass Device - July 13, 2017 Category: Medical Devices Authors: MassDevice Tags: News Well Plus 5 Source Type: news

Philips wins FDA nod for BlueControl psoriasis treatment device
Royal Philips (NYSE:PHG) said today it won FDA 510(k) clearance for its BlueControl wearable light therapy designed to treat mild psoriasis. The Amsterdam-based company’s BlueControl is designed as a rechargeable, wearable device which can be comfortably used on the arms, legs, elbows and knees using adjustable straps. The company won CE Mark approval in the European Union for the device in 2015. “As a company, we aim to improve people’s health with a broad portfolio of proven therapy solutions to enable patients with chronic conditions to manage their health at home. Philips BlueControl is a clinica...
Source: Mass Device - July 13, 2017 Category: Medical Devices Authors: Fink Densford Tags: 510(k) Food & Drug Administration (FDA) Regulatory/Compliance royalphilips Source Type: news

Psoriasis: Inequality or Individualized Care? Psoriasis: Inequality or Individualized Care?
How do socioeconomic and demographic factors influence biological drug prescribing for psoriasis? This commentary examines inequities across the globe.The British Journal of Dermatology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 13, 2017 Category: Consumer Health News Tags: Dermatology Journal Article Source Type: news

Molecular Differences Between Pediatric and Adult Psoriasis Plaques Molecular Differences Between Pediatric and Adult Psoriasis Plaques
The pathology of pediatric psoriasis differs from that of adult psoriasis, a finding that has implications for treatment, researchers suggest.Reuters Health Information (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - July 11, 2017 Category: Pathology Tags: Dermatology News Source Type: news

Novartis receives EU approval for Cosentyx label update
Novartis said that the Committee for Medicinal Products for Human Use has approved a label update for Cosentyx, the first interleukin-17A approved to treat psoriasis. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - July 6, 2017 Category: Pharmaceuticals Source Type: news

Novartis receives EU approval for Cosentyx label update
ZURICH (Reuters) - Novartis said that the Committee for Medicinal Products for Human Use (CHMP) has approved a label update for Cosentyx (secukinumab), the first interleukin-17A (IL-17A) approved to treat psoriasis. (Source: Reuters: Health)
Source: Reuters: Health - July 6, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Psoriatic Arthritis Often Remits During Pregnancy (CME/CE)
(MedPage Today) -- Arthritis trends favorably; psoriasis improves or remains stable (Source: MedPage Today Dermatology)
Source: MedPage Today Dermatology - July 5, 2017 Category: Dermatology Source Type: news

Sun Pharmaceutical signs agreement with Samsung BioLogics for psoriasis drug
The novel drug known as Tildrakizumab is currently under review by the US FDA and the European Medicines Agency (EMA). The value of the contract is about $55.5 million. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - July 4, 2017 Category: Pharmaceuticals Source Type: news

Sun Pharma inks $55.5-mn deal for anti-psoriasis drug
Sun Pharma said the approximate value of the contract will be USD 55.5 million, other financial details of the agreement are confidential. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - July 4, 2017 Category: Pharmaceuticals Source Type: news

Chinese man, 58, is dubbed 'Bark Man' by cruel neighbours
Li Xitian, 58, from Weihui in the Henan Province, has been living with the bizarre disorder, believed to be an extreme case of psoriasis, for nearly six decades. He now lives in isolation. (Source: the Mail online | Health)
Source: the Mail online | Health - June 30, 2017 Category: Consumer Health News Source Type: news

Arrien Pharmaceuticals signs license agreement for psoriasis treatment ARN-6039
Targeted therapeutics drug discovery and development company Arrien Pharmaceuticals has entered a worldwide license agreement with an unnamed US-based pharmaceutical firm for the clinical agent ARN-6039. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - June 29, 2017 Category: Pharmaceuticals Source Type: news

Novartis gets European OK for biosimilar of Amgen's Enbrel
ZURICH (Reuters) - Novartis's generics unit Sandoz said the European Commission approved Erelzi, its biosimilar to Amgen's Enbrel, to treat inflammatory diseases such as rheumatoid arthritis, psoriasis, and psoriatic arthritis. (Source: Reuters: Health)
Source: Reuters: Health - June 27, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Study Challenges Touted Link Between Eczema and Heart Disease
Researcher now probing whether more severe cases of the skin disorder increase odds of heart problemsSource: HealthDay Related MedlinePlus Pages: Eczema, Heart Diseases, Psoriasis (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - June 26, 2017 Category: Consumer Health News Source Type: news

Lancashire ANP named ‘psoriasis nurse of the year’
Zahira Koreja, an advanced nurse practitioner at East Lancashire Hospitals NHS Trust in Blackburn, has won the Psoriasis Nurse of the Year award for 2017. (Source: Nursing Times)
Source: Nursing Times - June 21, 2017 Category: Nursing Source Type: news

Medical News Today: Scientists find genetic underpinnings for eczema
A new study examines people with severe eczema and finds that a genetic mutation may cause the condition. The study also paves the way for a new treatment. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - June 21, 2017 Category: Consumer Health News Tags: Eczema / Psoriasis Source Type: news

Psoriasis, Depression, and Suicidality Psoriasis, Depression, and Suicidality
Psoriasis has been shown to be associated with an increased risk of depression and suicidality. How can we identify at-risk patients?Skin Therapy Letter (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 16, 2017 Category: Consumer Health News Tags: Dermatology Journal Article Source Type: news

Psoriasis May Itch as Intensely as Atopic Dermatitis Psoriasis May Itch as Intensely as Atopic Dermatitis
Itch intensity in moderate to severe plaque psoriasis can be substantial, and may be on a par with the notoriously itchy skin condition atopic dermatitis, new research suggests.Reuters Health Information (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - June 14, 2017 Category: Allergy & Immunology Tags: Dermatology News Source Type: news

Treating Psoriasis May Curb Vascular Inflammation Treating Psoriasis May Curb Vascular Inflammation
Improving psoriasis severity is associated with improvement in aortic vascular inflammation, suggesting that alleviating inflammation in the skin can favorably affect the vasculature, researchers say.Reuters Health Information (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - June 8, 2017 Category: Pathology Tags: Dermatology News Source Type: news

Eczema and psoriasis? THIS part of your morning routine could be triggering skin problems
ECZEMA and psoriasis are two of the skin conditions which affect 60 per cent of British people. (Source: Daily Express - Health)
Source: Daily Express - Health - June 8, 2017 Category: Consumer Health News Source Type: news

Psoriasis drug demonstrates positive outcome in two Phase III trials
A biologic agent known as tildrakizumab has demonstrated a positive outcome in two Phase III trials conducted by Harvard Medical School ’s Beth Israel Deaconess Medical Centre (BIDMC) in the US to treat patients with plaque psoriasis. (Source: Drug Development Technology)
Source: Drug Development Technology - June 7, 2017 Category: Pharmaceuticals Source Type: news

New psoriasis drug effective for three-quarters of patients in clinical trial
Two Phase 3 clinical trials have shown that tildrakizumab is effective and well-tolerated in patients with moderate-to-severe chronic plaque psoriasis. (Source: Health News - UPI.com)
Source: Health News - UPI.com - June 6, 2017 Category: Consumer Health News Source Type: news

Secukinumab and ixekizumab in psoriasis: Considerable added benefit for certain patients
(Institute for Quality and Efficiency in Health Care) There were notably more remissions than under the comparator therapies. In future, the analysis of symptoms should not be limited to improvements at one time point. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 2, 2017 Category: International Medicine & Public Health Source Type: news

Can Psoriasis Tx Diminish Atherosclerosis?
(MedPage Today) -- Observational study links improvements in skin, vascular inflammation (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - June 1, 2017 Category: Cardiology Source Type: news

Psoriasis Updates and Side-by-Side Treatment Review Psoriasis Updates and Side-by-Side Treatment Review
A look at the latest psoriasis news and most effective treatments.Medscape Dermatology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 31, 2017 Category: Consumer Health News Tags: Dermatology Article Source Type: news

Cancer therapy shows promise for psoriasis treatment
(Medical College of Georgia at Augusta University) HDAC inhibitors, already widely used to treat cancer, may be an effective therapy for psoriasis as well, scientists report. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - May 31, 2017 Category: Biology Source Type: news

Arthritis news: Drug could treat condition linked to psoriasis
PSORIATIC arthritis is linked to the skin condition psoriasis and is often painful, but a new drug could help significantly relieve symptoms. (Source: Daily Express - Health)
Source: Daily Express - Health - May 30, 2017 Category: Consumer Health News Source Type: news

Psoriasis: What can GPs do to deliver optimal care?
A new report has highlighted a severe lack of dermatology training and support within primary care. Dr Angelika Razzaque outlines the report's findings and what they mean for GPs. (Source: GP Online Education)
Source: GP Online Education - May 30, 2017 Category: Primary Care Tags: 15.10 Skin Problems Source Type: news

Medical News Today: Eczema herpeticum: Symptoms, diagnosis, and treatment
What is eczema, what is the herpes simplex virus, and what is eczema herpeticum? Learn about the treatments available and how it may be prevented. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - May 27, 2017 Category: Consumer Health News Tags: Eczema / Psoriasis Source Type: news

Promising Results for Drug to Fight Arthritis Linked to Psoriasis
Psoriatic arthritis causes painful joint swelling, but new medication Taltz might help Source: HealthDay Related MedlinePlus Pages: Medicines, Psoriatic Arthritis (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - May 26, 2017 Category: Consumer Health News Source Type: news

Promising Results for Ixekizumab Against Psoriatic Arthritis
FRIDAY, May 26, 2017 -- A new drug might help ease the pain and disability of a form of arthritis often linked to psoriasis. According to Stanford University researchers, psoriatic arthritis is an inflammatory joint disorder tied to an... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - May 26, 2017 Category: General Medicine Source Type: news

FDA approves Sun Pharma ’s tildrakizumab for moderate-to-severe plaque psoriasis
Indian company Sun Pharmaceutical Industries has received the US Food and Drug Administration (FDA) approval of the Biologics License Application (BLA) for tildrakizumab to treat patients with moderate-to-severe plaque psoriasis. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - May 24, 2017 Category: Pharmaceuticals Source Type: news

Dry and itchy skin? This is how to tell if you have eczema or psoriasis
DRY, itchy skin could be an early symptom of two skin conditions - eczema and psoriasis - but there are other ways to tell which you ’re suffering from. (Source: Daily Express - Health)
Source: Daily Express - Health - May 24, 2017 Category: Consumer Health News Source Type: news

Sun Pharma Announces US FDA Filing Acceptance of Biologics License Application (BLA) For Tildrakizumab
Tildrakizumab is being evaluated for treatment of moderate-to-severe plaque psoriasis MUMBAI, India and PRINCETON, N.J., May 24, 2017 -- (Healthcare Sales & Marketing Network) -- Sun Pharmaceutical Industries Ltd (Reuters: SUN.BO, Bloomberg: SUNP IN, N... Biopharmaceuticals, Dermatology, FDA Sun Pharma, Tildrakizumab, psoriasis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - May 24, 2017 Category: Pharmaceuticals Source Type: news

Study finds new genetic clues to psoriasis
A study by the University of Michigan has identified new genetic pathways and potential treatment targets for psoriasis. (Source: Health News - UPI.com)
Source: Health News - UPI.com - May 24, 2017 Category: Consumer Health News Source Type: news

US FDA accepts application for psoriasis drug: Sun Pharma
The FDA filing acceptance follows the acceptance of the regulatory filing of tildrakizumab by the European Medicines Agency (EMA) in March 2017. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - May 24, 2017 Category: Pharmaceuticals Source Type: news

Largest psoriasis meta-analysis to date yields new genetic clues
(Michigan Medicine - University of Michigan) The identification of 16 additional genetic markers will help researchers get closer to understanding how -- and why -- psoriasis develops. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 24, 2017 Category: International Medicine & Public Health Source Type: news